IL10 and obesity disorder: Therefore, based on the results of grafted MSCs tracing, we performed IL10-MSCs therapy through intravenous administration every 14 days, which could continuously release endogenous IL10 in vivo and played a sustained anti-inflammatory effect to treat HFD -induced obesity, leading to better therapeutic effects.